Target Research Articles

  1. The Future Is Ancient: Evolution, Metabolics, And AI 6/23/2026

    We caught up with Hannah Gordon, Ph.D., chief scientific officer of Enveda, to discuss why the future may depend more on decoding nature’s evolutionarily selected chemistry.

  2. Beyond Engineered Antibodies: Harnessing The Natural Human Repertoire 6/19/2026

    We caught up Srikanth Pendyala, MD, CMO of Infinimmune, to discuss the importance of learning directly from the human immune system itself in antibody research.

  3. How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 Of 3) 6/15/2026

    Rh incompatibility can make pregnancy dangerous. Rhogam helped protect my family and stands as a powerful example of unconventional drug discovery.

  4. 2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics 6/11/2026

    Startup founders of Resilientia Tx discuss protecting cancer patients from radiation side effects, organ-on-a-chip discovery, Nucleate Boston, and early startup challenges.

  5. A New De Novo Protein Design Platform For GPCR Drug Discovery 6/9/2026

    Skape Bio and UW created an AI-driven platform to design miniproteins that modulate GPCRs in living cells, opening new paths for biologic drug discovery.

  6. Advancing Spatial Multiomics for Discovery: From Promise to Practice 6/5/2026

    Spatial multiomics offers extraordinary biological insight, but high costs, tissue bottlenecks, and unclear clinical relevance still limit its reach.

  7. Discovery Dialogues: Helen Bright, Ph.D., CSO of Centauri Tx 6/4/2026

    At PEGS Boston, Helen Bright, PhD explained how Centauri’s CTX187 harnesses innate immunity to fight resistant gram-negative infections and support better outcomes.

  8. DDW 2026 Signalled The Next Era Of Competitive Landscape In IBD 6/2/2026

    At the DDW 2026 meeting, the IBD landscape was portrayed as increasingly competitive and diversified, with emerging players and novel mechanisms challenging established standards of care.

  9. Oncology Drug Discovery Is Targeting The Wrong Problem 5/21/2026

    There is a growing tension between what we measure and what ultimately matters. This disconnect raises an uncomfortable but necessary question: are we targeting the right problem?

  10. GLP-1 Receptor Agonists: Metabolism, Reward Biology, And AI-Driven Drug Discovery 5/6/2026

    For drug discovery teams, the central question is whether metabolic signaling pathways can serve as a tractable new entry point into addiction therapeutics.